model updat thought speak
compani second opinion
maintain outperform rate increas target price
updat model earn incorpor
commentari confer call follow convers
compani compani still face number headwind
see pace deliv mid-singl digit ep growth although admittedli
boost addit incom compani
expect expect fundament outlook improv
generic/biosimilar headwind eas key pharma product
current blockbust stelara imbruvica darzalex newer
asset spravato esketamin tremfya help drive growth
on-going talc litig remain overhang investor wait
consum medic devic segment deliv growth
think pharma divis abl still drive stori maintain
outperform rate rais target price
target price blend dcf rel valuat
ep estim move
pleas let us know would like updat
compani model primari risk rate target price
slowdown key pharma growth driver disappoint data
on-going clinic trial signific chang drug price
us surpris verdict on-going talc litig
catalyst see pharma busi review may especi
time year navig challeng pharma
busi also approach time-frame lose
patent protect key asset zytiga ex-u xarelto us
imbruvica hope learn busi review next
gener pipelin asset allow continu growth
pharma segment whole top-line data tremfya
psoriat arthriti data esketamin suicid follow shortli
thereaft import catalyst approv decis xarelto
vte prevent stelara uc esketamin trd eu
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
price apr rate outperform target price analyst vamil divan
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
johnson johnson hold compani engag
 manufactur sale rang product health care
field oper compani organ busi
blue sky valuat base greater sale
imbruvica darzalex lai franchis market product
compar current base case assumpt blue sky valuat
base dcf driven wacc termin valu
grey sky valuat base lower sale
imbruvica darzalex lai franchis market product
compar current base case assumpt grey sky valuat
base dcf driven wacc termin valu
 close
opportun speak member ir team follow
confer call gain addit clariti dynam around certain product
well bake expect go forward
summar compani answer question
 clarifi one-tim price benefit pharma segment
must forecast rebat channel variou true-up per quarter remicad y/i
comp impact stelara favor true-up invokana also factor half
 net oi drove increas guidanc
primarili asp given size transact purchas price alloc fine tune estim
relat one-tim cost also variou one-tim transact relat small bd
addit small amount ci labo
 quantifi impact see compass far much
cad/pad opportunity/your expect
hope cad/pad help off-set donut hole impact think take time
fulli materi howev earli feedback posit patient popul twice
exist current indic also pursu medic ill popul
 quantifi donut hole impact make provisions/adjust
term rebat expect donut hole util xarelto includ
provis later year
biggest chang rate go account polici project
util donut hole full year spread rate full year get true-
up still grow volum share given amount goe channel
impact util channel alon volum offset
given donut hole price eros
 lawsuit xarelto impact use
chang dynam bayer split settlement cost necessarili
direct link litig sale declin sale declin primarili relat medicar donut
 approxim rems-certifi center mention
prepar remark certifi date updat figur
mention addit sinc launch product march
figur end quarter today two week
 mani total center target think ramp
beyond esketamin
put year forecast small amount sale expect slow
ramp take educ effort encourag broad base interest
 think launch trajectori product given competit
market
target solid tumor area focu import initi indic patient
us typic patient elig mutat howev
potenti alter mani type diseas give blockbust
 volum price declin quarter
primarili price declin sinc last year volum current
infliximab market remicad share loss necessarili inflectra howev sinc
inflectra gain share expect eros us seem reason
market grow healthi rate under-penetrated remicad run
place due primarili price declin
 give color auri acquisit accretive/dilut
see expect benefit sinc target
market devic segment growth
auri early-stag compani look guidanc dilut earn off-set
midpoint guidanc chang accret
revenu current small
 impact ci hold acquisit date much
sale impact see beauty/skin segment
equiti stake bought japan arm sale japan japan drag
summari jnj result along comparison estim prior report figur
provid figur
us million unless otherwis state
compani data credit suiss estim streetaccount factset consensu
sustenna/ schiz sale sale salescost expensesoper expens expensenonoper incom incom net countpf dilut forecastgrowthgrowthvarianceep charl martineau pm univers toronto
figur cs comparison guidanc
us million unless otherwis state
compani data credit suiss estim streetaccount factset consensu
us million unless otherwis state
us million unless otherwis state
us million unless otherwis state
good expens incom expens share continu analysisgross margin oper margin per changestot ep charl martineau pm univers toronto
us million unless otherwis state
us million unless otherwis state
us million unless otherwis state
compani mention price
vamil divan md certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view express
report
